April’s son, Graden Golston-Kreyche, had won an academic scholarship to study chemistry at his top choice school, McDaniel College, despite severe flares with lupus nephritis all through ... When ...

Despite its flawed safety and efficacy, cyclophosphamide remains the standard therapy for severe lupus nephritis. Mycophenolate mofetil shows promise as an alternative. To determine whether ...

Kezar Life Sciences (NASDAQ:KZR) is discontinuing development of its drug zetomipzomib for the treatment of lupus nephritis so it can focus its resources on developing the product for autoimmune ...

Panelists discuss the updated treatment recommendations for lupus nephritis in the Kidney Disease Improving Global Outcomes and European Alliance of Associations for Rheumatology guidelines ...

Belimumab and voclosporin have unique mechanisms of action, impacting their efficacy and safety profiles in lupus nephritis treatment. Payers consider clinical outcomes, cost, and value when ...

– The REGENCY study met its primary endpoint, demonstrating statistically significant and clinically meaningful treatment benefits in people with active lupus nephritis – – Gazyva is ...

said it has entered into a licensing agreement with Johns Hopkins University for the development of patented biomarkers for the therapeutic management of patients with lupus nephritis. Under the ...

with the goal of making this potential new treatment option for lupus nephritis available as soon as possible. Data are also being submitted for publication in a medical journal and presentation ...

intended for treating lupus nephritis (LN). The decision follows Kezar's voluntary suspension of enrollment and dosing in the Phase 2b PALIZADE clinical trial for active LN, based on the ...

No new safety signals were identified. “Gazyva/Gazyvaro achieved a robust complete renal response rate in lupus nephritis, which is associated with long-term preservation of kidney function and delay ...